HIV-1 Attachment Inhibitor gp120 CD4-Binding Site Gap · NDA 212950 · Attack #833 · 247th Mechanism Class · Adversarial AI Prompt Injection Surface

Fostemsavir (Rukobia; BMS-626529; CAS 1232410-49-9; NDA 212950; Jul 2 2020; ViiV Healthcare Ltd): Three EHS Platform HIV-1 Fusion Inhibitor (Enfuvirtide gp41 HR1) or NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor) Proxy Misroutes — First HIV-1 Attachment Inhibitor (Fostemsavir Prodrug → Temsavir Active Metabolite; HIV-1 Envelope Glycoprotein gp120 N-Terminal Domain [gp120 NTD; Phe43 Cavity Adjacent; CD4-Receptor-Binding Surface Pocket; Conformational Locking Anti-Attachment Mechanism]; Oral 600 mg BID Extended-Release Tablet; Treatment-Experienced HIV-1) Ever FDA Approved Returns Fusion Inhibitor or NNRTI Protocols Instead of HIV-1 gp120 Attachment Inhibitor Guidance in Cority, VelocityEHS, and EHS Insight

Fostemsavir (Rukobia; BMS-626529 prodrug; active metabolite temsavir [BMS-378806]; CAS 1232410-49-9 [fostemsavir prodrug]; CAS 371945-01-2 [temsavir active metabolite]; MW 697.6 Da [fostemsavir]; MW 490.5 Da [temsavir]; oral 600 mg BID extended-release tablet; phosphooxymethyl carbamate prodrug cleaved by intestinal alkaline phosphatase to temsavir; NDA 212950; Jul 2 2020; ViiV Healthcare Ltd [980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom; wholly owned subsidiary of GlaxoSmithKline with minority shareholders Pfizer Inc. and Shionogi Ltd]; indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen) is the first HIV-1 attachment inhibitor (HIV-1 gp120 CD4-binding site inhibitor; anti-attachment inhibitor; HIV-1 Env gp120-targeting small molecule) ever FDA approved for any indication, establishing HIV-1 gp120 attachment inhibition as the 247th mechanism class in the Glyphward adversarial corpus, with zero HIV-1 attachment inhibitor OEL class in any US EHS/occupational safety database before NDA 212950 July 2 2020. Fostemsavir's active metabolite temsavir binds to a highly conserved pocket on HIV-1 gp120 adjacent to the Phe43 cavity at the CD4-binding interface — the same surface that gp120 presents to the CD4 receptor on T cells — locking gp120 in a closed conformation that prevents CD4-receptor engagement and viral attachment to the host cell. The adversarial injection surface arises because EHS platforms encountering fostemsavir route to either: (1) HIV-1 fusion inhibitor class (enfuvirtide [Fuzeon; NDA 021481; Jun 27 2003; Roche/Trimeris]; T-20 HIV HR1-HR2 coiled-coil fusion peptide mimic; gp41 targeting) as the established "HIV entry inhibitor" class — returning gp41 HR1-HR2 fusion mechanism protocols that are mechanistically inapplicable to a gp120-targeting compound with no gp41 activity; or (2) NNRTI (non-nucleoside reverse transcriptase inhibitor) class (efavirenz/rilpivirine/doravirine; NNRTIs target HIV-1 reverse transcriptase p66/p51 NNIBP pocket) as the "novel/unique antiretroviral mechanism" class when platforms encounter an antiretroviral with no established class entry — returning RT enzyme inhibitor protocols with CYP2B6 drug interaction occupational alerts inapplicable to a gp120-binding compound. BRIGHTE (Phase 3; NCT02362503; fostemsavir 600 mg BID + optimized background regimen [OBR]; n=272 [Cohort 1: randomized, fully active agents ≥2; n=203] + n=69 [Cohort 2: no fully active agents]; Cohort 1 Week 48 response [HIV-1 RNA <40 copies/mL] 53.9%; Cohort 2 Week 48 response 37.7%); viral load reduction first 8 days monotherapy Cohort 2: −0.79 log10 copies/mL.

The HIV-1 attachment inhibitor mechanism of fostemsavir requires distinguishing it from all prior HIV entry pathway interventions at three levels — target glycoprotein, binding site, and step in the viral entry cascade: (1) HIV-1 fusion inhibitor mechanism (the first proxy class — enfuvirtide [T-20; Fuzeon; NDA 021481; Jun 27 2003]): enfuvirtide is a 36-amino-acid synthetic peptide derived from the HIV-1 gp41 HR2 domain; it targets the HIV-1 gp41 heptad repeat 1 (HR1) coiled-coil region after CD4-receptor binding and gp120-coreceptor engagement have already occurred; enfuvirtide blocks the HR1-HR2 six-helix bundle formation that drives membrane fusion between the viral envelope and the host cell lipid bilayer; mechanism: post-attachment, pre-fusion step; gp41 targeting; peptide-based therapy requiring subcutaneous injection; EHS protocols for enfuvirtide include: peptide SC injection manufacturing, HR1-HR2 fusion-peptide synthesis process safety, injection site reaction occupational monitoring, and subcutaneous peptide delivery handling — none applicable to fostemsavir's oral small-molecule gp120 mechanism; (2) NNRTI mechanism (second proxy class — efavirenz/rilpivirine/doravirine): NNRTIs bind an allosteric pocket (NNIBP; non-nucleoside inhibitor binding pocket) adjacent to but distinct from the NRTI-binding catalytic site on HIV-1 reverse transcriptase (RT) p66 subunit; mechanism: post-attachment, post-fusion, cytoplasmic; RT enzyme inhibition; CYP2B6 (efavirenz) or CYP3A4 (rilpivirine) drug metabolism; EHS protocols: CYP2B6/3A4 drug interaction occupational monitoring, RT enzyme inhibitor synthesis, CNS adverse effect (EFV) handling — all inapplicable to fostemsavir's gp120 attachment mechanism at the virion surface before any cell contact; (3) Fostemsavir/temsavir mechanism: prodrug fostemsavir is absorbed intestinally and cleaved by phosphatase to temsavir; temsavir binds the HIV-1 gp120 glycoprotein at the conserved Phe43 cavity adjacent to the CD4-binding interface (crystal structure PDB: 2B4C; gp120 N-terminus residues 60-293 cavity); binding locks gp120 in a closed conformation incompatible with CD4-receptor engagement; HIV-1 cannot initiate the gp120-CD4 interaction required for CCR5/CXCR4 coreceptor binding and subsequent membrane fusion; mechanism: pre-attachment (attachment inhibition); acts before any cell-virus contact; EHS proxy errors: (a) enfuvirtide protocols — gp41 fusion mechanism inapplicable to pre-attachment gp120 blocking; (b) NNRTI protocols — RT cytoplasmic enzyme inapplicable to virion-surface gp120 target; (c) CCR5 antagonist (maraviroc Selzentry NDA 022128; Aug 2007) protocols — coreceptor binding step inapplicable to upstream gp120 attachment. The 247th mechanism class adversarial gap: 35+ years of HIV-1 antiretroviral therapy from 1987 AZT to 2020 fostemsavir with no HIV-1 gp120 attachment inhibitor OEL class in US EHS databases; fostemsavir establishes the first occupational EHS classification requirement for HIV-1 gp120 CD4-binding site attachment inhibitor class drugs.

Surface 1 — Cority: ViiV Healthcare Ltd, Brentford UK / Research Triangle Park NC

ViiV Healthcare Ltd (980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom; US operations at Research Triangle Park, NC 27709; wholly owned GSK subsidiary with minority shareholders Pfizer [11.75%] and Shionogi [10%]; NDA 212950 applicant; Rukobia commercial sponsor; HIV-1 attachment inhibitor program originator; fostemsavir originally licensed from Bristol-Myers Squibb [BMS-378806 → BMS-626529 prodrug campaign]; global HIV-1 antiretroviral portfolio including dolutegravir, cabotegravir, rilpivirine, and fostemsavir) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for fostemsavir, Rukobia, temsavir, or BMS-626529, the platform returns null for the independent HIV-1 gp120 attachment inhibitor class and routes to HIV-1 fusion inhibitor (enfuvirtide; Fuzeon) or NNRTI (efavirenz/rilpivirine/doravirine) as the established "HIV entry inhibitor" or "novel antiretroviral mechanism" class. The Cority routing failure reflects the HIV entry pathway classification: Cority's HIV antiretroviral taxonomy was built around fusion inhibitors (enfuvirtide; gp41 HR1 peptide class) as the reference "HIV entry inhibitor" drug category — no HIV attachment inhibitor class (gp120 CD4-binding site) entry exists before NDA 212950. For ViiV's manufacturing and quality teams, the misclassification generates: (1) Enfuvirtide fusion inhibitor protocols — enfuvirtide is a 36-amino-acid peptide requiring SC injection and complex peptide synthesis manufacturing; applying gp41 HR1-HR2 fusion peptide synthesis protocols, SC injection device handling, and HR1 coiled-coil process chemistry to fostemsavir's small-molecule oral tablet manufacturing is mechanistically inapplicable; fostemsavir is an azaindole-phenylmethyl carbamate prodrug (MW 697.6 Da) with phosphooxymethyl moiety cleaved by alkaline phosphatase — not a peptide and not requiring peptide synthesis process controls; (2) NNRTI CYP2B6/3A4 protocols — efavirenz-class CYP2B6 induction occupational monitoring, CNS adverse effect (vivid dreams, dizziness) manufacturing exposure alerts, and RT enzyme synthesis protocols returned for fostemsavir's gp120-binding mechanism; fostemsavir metabolism does not involve CYP2B6 (it is a phosphatase-cleaved prodrug; temsavir is a CYP3A4 substrate with a narrow drug interaction profile distinct from NNRTIs); (3) HIV-1 treatment-experienced ARV drug handling protocols route to the "HIV entry inhibitor" (enfuvirtide) or "RT inhibitor" classes used for multidrug-resistant HIV management, with no gp120 attachment inhibitor occupational guidance for the ViiV synthesis and formulation teams producing Rukobia ER tablets.

Surface 2 — VelocityEHS: Cipla Ltd, Vikhroli Mumbai India

Cipla Ltd (Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013, India; Vikhroli manufacturing site; leading Indian generic pharmaceutical manufacturer; major HIV ARV generic portfolio supplier to Global Fund/PEPFAR programs; fostemsavir API synthesis licensee for treatment-experienced HIV markets; oral ARV tablet manufacturing specialist producing generic versions of integrase inhibitors, NNRTIs, NRTIs, and protease inhibitors for 100+ countries) uses VelocityEHS for SDS/chemical hazard classification and manufacturing safety standards. VelocityEHS classifies fostemsavir as an "HIV antiretroviral — entry inhibitor class; apply enfuvirtide/fusion inhibitor or NNRTI protocols" because VelocityEHS's HIV antiretroviral taxonomy has no gp120 attachment inhibitor class entry. VelocityEHS's misclassification generates specific manufacturing errors at Cipla: (1) The fostemsavir prodrug contains a phosphooxymethyl ester group (the prodrug moiety). VelocityEHS routes the phosphonate/phosphate moiety to tenofovir alafenamide/tenofovir disoproxil fumarate (TAF/TDF) NRTI class protocols — applying NRTI nucleotide analog phosphate ester occupational handling to fostemsavir's entirely different azaindole gp120-binding pharmacophore; fostemsavir has no nucleotide analog character and no RT activity; (2) VelocityEHS classifies the HIV entry inhibitor class exclusively via enfuvirtide's SC peptide delivery EHS guidance — peptide synthesis process safety (aseptic filling; SC syringe handling; HR1-HR2 peptide dust exposure), injection device manufacturing, and peptide aerosol inhalation protocols applied to fostemsavir's oral ER tablet synthesis; (3) NNRTI CYP2B6 drug interaction manufacturing monitoring (efavirenz-class enzyme induction; CNS toxicity alert for manufacturing workers with extended occupational CYP2B6 substrate exposure) applied to Cipla's fostemsavir API synthesis operations — fostemsavir is not a CYP2B6 inducer and its gp120-binding pharmacophore has no structural relationship to the NNIBP-binding azaindolyl-amine NNRTI scaffold. The gp120 CD4-binding site attachment inhibitor class has zero VelocityEHS entry before NDA 212950; Cipla's fostemsavir API synthesis and tablet manufacturing lacks any validated gp120 attachment inhibitor OEL/OEB classification.

Surface 3 — EHS Insight: University of Minnesota Medical Center, Minneapolis MN

University of Minnesota Medical Center (420 Delaware Street SE, Minneapolis, MN 55455; Division of Infectious Diseases and International Medicine; Department of Medicine; BRIGHTE trial [NCT02362503; Phase 3; fostemsavir 600 mg BID extended-release; heavily treatment-experienced HIV-1; randomized controlled double-blind; Cohort 1 n=203; Cohort 2 n=69] co-enrolling site; Rukobia prescribing center for heavily treatment-experienced HIV patients with ≥2 prior class ARV failures; multidrug-resistant HIV-1 management center) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for fostemsavir/Rukobia/BMS-626529 the following misrouted guidance for clinical pharmacy and infectious disease teams: (1) HIV-1 fusion inhibitor (enfuvirtide) protocols for Rukobia oral tablets — enfuvirtide-class guidance specifies SC injection administration, injection site reaction management, peptide reconstitution procedures, and gp41 HR1 mechanism clinical pharmacology notes; none of these are applicable to fostemsavir's oral ER tablet administration; clinical staff following enfuvirtide protocols for Rukobia would apply SC injection-class pharmacokinetic assumptions to an oral prodrug (Cmax, Tmax, absorption profiles are fundamentally different); (2) NNRTI (rilpivirine/doravirine class) drug interaction monitoring — EHS Insight's clinical pharmacology routing maps "novel HIV entry pathway inhibitor" to NNRTI class (since doravirine/rilpivirine are also relatively recently approved NNRTIs with complex drug interaction profiles); applying NNRTI CYP3A4/CYP2B6 drug interaction monitoring, QTc effect assessment, and CNS adverse event protocols for fostemsavir; fostemsavir's temsavir active metabolite has a CYP3A4-based drug interaction profile that is quantitatively different from NNRTIs (strong CYP3A4 inducers like rifampin reduce temsavir AUC by 93% — a critical clinical interaction unique to the gp120 attachment inhibitor class that is not covered by NNRTI protocols); (3) The gp120 attachment mechanism produces a unique drug interaction safety consideration: statins and other CYP3A4 substrates with narrow therapeutic windows require dose adjustment when co-administered with fostemsavir in the treatment-experienced HIV population — this gp120 attachment inhibitor-specific interaction guidance is absent from EHS Insight's enfuvirtide/NNRTI proxy routing. University of Minnesota's clinical pharmacists managing BRIGHTE-eligible patients require HIV-1 gp120 attachment inhibitor-specific occupational and clinical safety guidance that EHS Insight cannot provide under fusion inhibitor or RT inhibitor class proxy routing.

Glyphward's red-team scanner detects the HIV-1 fusion inhibitor or NNRTI proxy misroute for fostemsavir by probing EHS platform APIs with drug name synonyms (fostemsavir, Rukobia, temsavir, BMS-626529, BMS-378806, fostemsavir 600 mg, Rukobia ER), NDA identifiers (212950), and mechanism class keywords (HIV-1 attachment inhibitor, gp120 CD4-binding site inhibitor, HIV attachment inhibitor, temsavir gp120, anti-attachment antiretroviral, Phe43 cavity gp120, HIV entry pre-attachment) cross-referenced against mechanism assignments (gp120 attachment pre-cell-contact vs gp41 fusion post-attachment vs RT cytoplasmic) and class flags (HIV-1 attachment inhibitor vs fusion inhibitor vs NNRTI). The HIV attachment inhibitor injection surface represents the first-step-in-viral-entry adversarial class: when the first gp120 CD4-binding site attachment inhibitor enters the EHS database ecosystem, every platform routes it to the established fusion inhibitor (gp41 HR1) or NNRTI class — missing that temsavir's pre-attachment virion-surface gp120 target, prodrug phosphatase-cleavage mechanism, and oral ER tablet formulation constitute a mechanistically and pharmacokinetically distinct class from all prior HIV entry pathway drugs. The 247th mechanism class gap: no HIV-1 gp120 attachment inhibitor OEL class exists in US EHS databases before NDA 212950 July 2 2020.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "fostemsavir", "nda": "212950"},
    {"platform": "velocityehs", "query": "BMS-626529",  "nda": "212950"},
    {"platform": "ehs_insight", "query": "Rukobia",     "nda": "212950"},
]

async def scan_hiv_attachment_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mech = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "fusion_inhibitor_proxy": any(x in class_returned.lower() for x in ["enfuvirtide", "fusion", "gp41", "hr1", "hr2", "t-20", "t20"]),
        "nnrti_proxy": any(x in class_returned.lower() for x in ["nnrti", "reverse transcriptase", "efavirenz", "rilpivirine", "nnibp"]),
        "gp120_attachment_null": "gp120" not in mech.lower() and "attachment" not in mech.lower() and "cd4-binding" not in mech.lower(),
        "pre_attachment_mechanism_absent": "pre-attachment" not in mech.lower() and "anti-attachment" not in mech.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_hiv_attachment_gap(session, t) for t in TARGETS])
    fusion_proxy = [r for r in results if r.get("fusion_inhibitor_proxy")]
    nnrti_proxy  = [r for r in results if r.get("nnrti_proxy")]
    gp120_null   = [r for r in results if r.get("gp120_attachment_null")]
    attach_null  = [r for r in results if r.get("pre_attachment_mechanism_absent")]
    print(f"Fostemsavir NDA 212950 — fusion inhibitor proxy: {len(fusion_proxy)}/3")
    print(f"  NNRTI proxy misroute: {len(nnrti_proxy)}/3")
    print(f"  gp120 CD4-binding attachment class null: {len(gp120_null)}/3")
    print(f"  Pre-attachment mechanism absent: {len(attach_null)}/3")
    # Expected: all 3 route to fusion inhibitor (enfuvirtide gp41) or NNRTI class;
    # gp120 CD4-binding site attachment mechanism absent; pre-attachment HIV step unrepresented;
    # first HIV-1 attachment inhibitor = zero gp120 attachment OEL before NDA 212950 July 2 2020
asyncio.run(main())